bezafibrate / Generic mfg. - LARVOL DELTA

A RARE CASE OF RHABDOMYOLYSIS LEADING TO PIGMENT NEPHROPATHY AND ACUTE KIDNEY INJURY REQUIRING HAEMODIALYSIS (ISN-WCN 2026) - "Recent studies have explored the role of triheptanoin, a specialized artificial fat substitute, in managing this disorder. Additionally, experimental pharmacological treatments such as bezafibrate and REN-01 (a PPAR-delta agonist) are being investigated for their potential in enhancing fatty acid oxidation.(10,11)Conclusion Recurrent rhabdomyolysis due to adult-onset VLCAD deficiency is uncommon but clinically significant. Identifying characteristic symptoms, particularly those linked to fasting, physical exertion, or infections, is essential for timely diagnosis. Implementing preventive measures, including appropriate lifestyle adaptations and dietary strategies, can help lower the risk of metabolic decompensation and subsequent episodes."

Clinical • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Genetic Disorders • Glomerulonephritis • Hepatology • Hypertrophic Cardiomyopathy • Hypoglycemia • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Musculoskeletal Pain • Myositis • Nephrology • Renal Disease • ACADVL • MB

A CASE OF LIPOPROTEIN GLOMERULOPATHY WITH APOE SENDAI VARIANT SUCCESSFULLY MAINTAINED WITHOUT PROGRESSION FOR EIGHT YEARS UNDER PEMAFIBRATE-BASED THERAPY (ISN-WCN 2026) - "Since proteinuria persisted, additional ARB, eicosapentaenoic acid (EPA), an SGLT2 inhibitor, and ezetimibe were introduced...Although bezafibrate has been reported to be effective in some cases, in this case, renal function had already declined at diagnosis, and bezafibrate was contraindicated. This is a rare case of LPG with APOE Sendai mutation in which renal function was preserved for eight years under pemafibrate-based therapy. Pemafibrate may represent a safe and effective treatment option for patients with LPG and renal impairment."

Clinical • Cardiovascular • Glomerulonephritis • Hematological Disorders • Ischemic stroke • Rare Diseases • Thrombosis • APOE

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis. (PubMed, Aliment Pharmacol Ther) - "PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials."

HEOR • Journal • Retrospective data • Review • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

The number needed to treat with bezafibrate as second-line therapy to prevent liver transplantation or death in people with primary biliary cholangitis (EASL 2026) - No abstract available

Clinical • Hepatology • Immunology • Primary Biliary Cholangitis • Transplantation

Elafibranor tolerability and response in patients with primary biliary cholangitis previously treated with bezafibrate: a real-world single-centre experience (EASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatology • Immunology • Primary Biliary Cholangitis

Real-World Therapy Response in Primary Biliary Cholangitis: Insights from a Belgian Monocentric Cohort. (BWG 2026) - "In Belgium, bezafibrate is used off-label for patients who are non-responders or intolerant to ursodeoxycholic acid (UDCA), while newer agents such as seladelpar and elafibranor are in the process of obtaining market access approval in Europe. This first Belgian real-world analysis demonstrates that fibrates are widely used in PBC patients and are independently associated with complete normalization of ALP. Nevertheless, the substantial discontinuation rate of fibrates and the proportion of patients who fail to achieve ALP normalization underscore the need for additional therapeutic options in PBC management."

Clinical • Real-world • Real-world evidence • Cholestasis • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Musculoskeletal Pain • Primary Biliary Cholangitis

Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia. (PubMed, J Vet Intern Med) - "Long-term use of BZF proved safe and effective for most dogs with primary and secondary hypertriglyceridemia."

Journal • Retrospective data • Dyslipidemia • Endocrine Disorders • Hypertriglyceridemia

Comparative effectiveness of pemafibrate versus bezafibrate on hepatic and vascular endothelial function in patients with coronary artery disease and metabolic dysfunction-associated steatotic liver disease. (PubMed, Front Endocrinol (Lausanne)) - "Both treatments significantly lowered HOMA-IR; however, the decrease was similar between the groups (P = 0.724). Pemafibrate is more effective than bezafibrate at reducing ALT levels while offering similar beneficial effects on insulin resistance and endothelial function in CAD patients with MASLD."

HEOR • Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Bezafibrate prolongs hypothermia induced by an A1 adenosine receptor agonist in CBA/N mice. (PubMed, J Vet Med Sci) - "Both receptors are considered key factors in controlling torpor and/or hibernation; however, a synergistic relationship between these receptors has not been reported. Therefore, our findings suggest that metabolic activation of lipid catabolism via PPARα signaling may potentiate the hypothermic effects induced by A1AR activation."

Journal • Preclinical • Metabolic Disorders • PPARA

Pan-PPAR agonist bezafibrate alleviates psoriasis by suppressing LCN2-dependent ferroptosis. (PubMed, Free Radic Biol Med) - "Lipidomic analysis revealed BEZ reversed imiquimod (IMQ)-induced accumulation of pro-ferroptotic lipids including ceramides, PE(36:4;1O), PE(34:2;1O), and PE(16:0_18:1;O). Importantly, BEZ significantly suppressed LCN2 expression, and LCN2 overexpression abolished BEZ's protective effects against ferroptosis and inflammation in keratinocytes. These findings demonstrate that BEZ alleviates psoriasis by inhibiting ferroptosis through LCN2 suppression and lipid metabolic reprogramming, highlighting the therapeutic potential of pan-PPAR activation as a multifaceted strategy for inflammatory skin disorders."

Journal • Dermatology • Immunology • Inflammation • Metabolic Disorders • Psoriasis • ACSL4 • ALOX12 • GPX4 • LCN2

Targeting mitochondrial dysfunction across the lifespan: Role of bezafibrate in neurodevelopment and neurodegeneration. (PubMed, Neural Regen Res) - No abstract available

Journal • CNS Disorders • Metabolic Disorders

A bezafibrate bearing Pt(IV) prodrug triggers ferroptosis via modulating lipid metabolism in lung cancer cells. (PubMed, J Biol Inorg Chem) - No abstract available

Journal • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor

Mechanistic Dichotomy in Sulfate Radical Anion-Mediated Oxidative Synthesis of Activated N-Hydroxysuccinimide Esters. (PubMed, J Org Chem) - "The synthetic utility was demonstrated by the preparation of marketed drugs, including moclobemide, procainamide, acecainide, and bezafibrate, with moclobemide further synthesized on a 100 g scale, highlighting the practicality and industrial relevance of the process. The results suggest that the generation and subsequent radical-radical coupling of acyl and succinimide-N-oxyl radicals constitute the most favorable pathway, while alternative radical and cationic routes may also contribute under reaction conditions. This study not only advances an efficient and scalable amide synthesis but also broadens the mechanistic understanding of sulfate radical anion reactivity in aromatic systems."

Journal

Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial. (PubMed, Hepatol Commun) - "BZF decreased cholestasis markers in survivors of BA with native livers, indicating its potential as an alternative to delayed liver transplantation for this population."

Journal • P2 data • Cholestasis • Hepatology • Liver Failure • Nephrology • Renal Disease • Transplantation

Pharmaceuticals, Pesticides, and Poly- and Perfluoroalkyl Substances at Surface Water Occurrence Levels-Impact of Compound Specific Physicochemical Properties on Nanofiltration and Reverse Osmosis Processes. (PubMed, Membranes (Basel)) - "Size exclusion and electrostatic interactions were identified as the primary removal mechanisms, with hydrophobic interactions having a lower impact, particularly for carbamazepine, bezafibrate, and perfluorooctane sulfonic acid (PFOS). Addition of sodium chloride (3 g L-1) decreased rejection of most negatively charged compounds due to suppression of membrane surface charge, although clarithromycin and ofloxacin exhibited improved rejection. Presented results provide fundamental insight into compound-specific membrane rejection and highlight the importance of membrane-solute interactions under environmentally realistic conditions. The results support further optimization of NF and RO for targeted compound rejection and provide a baseline for data-driven membrane process modeling."

Journal

Retraction Notice: Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. (PubMed, J Epilepsy Res) - "[This retracts the article on p. 45 in vol. 4, PMID: 25625088.]."

Journal • CNS Disorders • Epilepsy

Targeting PGC-1α axis Rescues Aberrant Development from Thyroid Hormone Defect in Brain Organoids. (PubMed, Pharmacol Res) - "Most importantly, pharmacological stimulation of the PGC-1α axis with Nicotinamide Riboside or Bezafibrate rescues mitochondrial bioenergetics and neuronal development, effectively correcting aberrant brain organoid maturation despite T3 deficiency. These findings reveal for the first time the role of T3 in supporting neurodevelopment via activation of mitochondrial β-oxidation and OXPHOS biogenesis, and identify the PGC-1α axis as a promising therapeutic avenue for otherwise intractable disorders linked to thyroid hormone deficiency."

Journal • Developmental Disorders • Mental Retardation • PPARGC1A

Investigating the therapeutic mechanisms of dental pulp stem cells in Parkinson's disease: A bioinformatics-based multi-omics analysis. (PubMed, Biochem Biophys Res Commun) - "Molecular docking further demonstrated strong predicted binding affinities for MGAT1 with SRC kinase inhibitor II (-8.58 kcal/mol), ARRB2 with bezafibrate (-5.19 kcal/mol), and COL15A1 with ruxolitinib (-6.32 kcal/mol). In vivo qPCR analysis in the PD rat model confirmed downregulation of ARRB2 and MGAT1 and upregulation of COL15A1 (p < 0.05), supporting the bioinformatics findings. Overall, this multi-level analysis highlights potential mechanisms between DPSCs and PD, and identifies candidate genes and drug targets that may inform future therapeutic strategies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study. (PubMed, Am J Gastroenterol) - "In this real-world nationwide study, the one-year fibrate discontinuation rate was substantial. However off-label use of bezafibrate was associated with reductions in the biochemical markers of cholestasis in PBC, which were associated with clinical outcome in this setting of second line therapy."

Journal • Real-world evidence • Cholestasis • Hepatology • Immunology • Liver Failure • Primary Biliary Cholangitis • Transplantation

Development of a methodology in an automated system for analysis of naproxen and bezafibrate in in-situ formation using a deep eutectic solvent by liquid chromatography. (PubMed, J Chromatogr A) - "The precision results were lower than 15.9% and recoveries ranged from 71 to 102%. The greenness of the methodology was confirmed using the AGREEprep tool, demonstrating that the proposed strategy offers a sustainable, selective, and high-throughput alternative for the determination of emerging pharmaceutical contaminants in aquatic environments."

Journal

mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes. (PubMed, Pharmacogenomics J) - "Notably, bezafibrate, a PPAR pan-agonist, demonstrated substantial genetic overlap with T2D loci, supporting its potential in metabolic disease. This study introduces a genetically informed pipeline for drug repurposing based on multi-trait gene set analysis."

Journal • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus • KCNQ1OT1 • PPARG

Targeting PRDM1 to Enhance CAR T Cell Therapy Against Diffuse Large B Cell Lymphoma (DLBCL) (ASH 2024) - "From a translational perspective, we assessed the potential synergistic effects of a PGC1α agonist, bezafibrate, with CAR T cells...Building upon a correlation between PRDM1 expression and CAR T cell dysfunction, we aim to pioneer the use of PRDM1 and/or its target genes as novel biomarkers for predicting clinical responses of r/r DLBCL patients to CAR T cell therapy. Our endeavors will better elucidate the mechanisms by which PRDM1 determines the fates of clinical CAR T cell products and the translational potential of targeting PRDM1/PRDM1-mediated pathways to generalize the application of CAR T cell therapy against cancers."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD8 • PPARGC1A • PRDM1

Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis (ISPOR-EU 2025) - "Pruritus is a common symptom in PBC, especially in female patients. However, treatment patterns in Germany show decreasing reliance on cholestyramine, with increasing use of alternative therapies."

Reimbursement • US reimbursement • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation